[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338138-105":59,"doc-detail-338138-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","high-expression-of-phosphoglycerate-dehydrogenase-predicts-poor-outcome-in-patients-with-high-grade-serous-ovarian-cancer","High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer","","High-grade serous ovarian cancer (HGSOC) has high mortality and frequent recurrences, motivating the search for prognostic biomarkers. In a cohort of advanced-stage patients treated between 2008 and 2015, phosphoglycerate dehydrogenase (PHGDH) expression was measured by immunohistochemistry and classified as low or high. PHGDH-high tumors correlated with higher FIGO stage and greater neoadjuvant chemotherapy use, and showed significantly worse survival even after adjusting for confounders.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/high-expression-of-phosphoglycerate-dehydrogenase-predicts-poor-outcome-in-patients-with-high-grade-serous-ovarian-cancer/338138/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/high-expression-of-phosphoglycerate-dehydrogenase-predicts-poor-outcome-in-patients-with-high-grade-serous-ovarian-cancer/338138.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main prognostic question addressed in the study?","Question",{"text":112,"@type":113},"The study evaluates whether phosphoglycerate dehydrogenase (PHGDH) expression predicts survival outcomes in high-grade serous ovarian cancer (HGSOC).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was PHGDH expression measured and categorized?",{"text":117,"@type":113},"PHGDH expression was assessed by immunohistochemistry and scored by staining intensity multiplied by the percentage of positive cells, then grouped into “low” or “high” using a survival-discriminative cutoff.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical factors were associated with PHGDH-high tumors?",{"text":121,"@type":113},"PHGDH-high tumors were linked to higher FIGO stage and increased use of neoadjuvant chemotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338138,1790171199,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52,"preview_page_count":19,"preview_urls":144},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer  \nLilian van Wagensveld, MD*, 1,2,3, Tom Van Nyen, PhD4,5, Daniela Annibali, PhD4,6,  \nGabe S. Sonke, MD, PhD7, Roy F.P.M. Kruitwagen, MD, PhD3,8, Frederic Amant, MD, PhD4,6,9, Hugo M. Horlings, MD, PhD2  \n1Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), 3511 DT Utrecht, The Netherlands, 2Department of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands,  \n3GROW, School for Oncology and Reproduction, 6229 HX Maastricht, The Netherlands,  \n4Gynecological Oncology Laboratory, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000 Leuven, Belgium, 5Division of Oncogenomics, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands,  \n6Department of Gynaecologic Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands, 7Department of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands, 8Department of Obstetrics and Gynecology, Maastricht University Medical Centre, 6229 HX Maastricht, The Netherlands, 9Department of Obstetrics and Gynecology, University Hospitals Leuven and Department of Oncology, 3000 Leuven, Belgium  \n* Corresponding author: Lilian van Wagensveld, MD, Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), 3511 DT Utrecht, The Netherlands (l.vanWagensveld@iknl. nl) .  \nAbstract  \nIntroduction: High-grade serous ovarian cancer (HGSOC) is characterized by high mortality and prevalent recurrences. This study investigates the prognostic value of phosphoglycerate dehydrogenase (PHGDH) in HGSOC which has been linked to metabolic reprogramming and recurrences in other cancers.  \nMethods: Data from 306 patients with advanced-stage HGSOC treated between 2008 and 2015 were analyzed. PHGDH expression levels were determined using immunohistochemistry and categorized as “low” or “high.”  \nResults: PHGDH-high was associated with higher FIGO stage and increased use of neoadjuvant chemotherapy. Patients with PHGDH-high tumors had significantly worse survival than PHDH-low, even after adjusting for confounding factors.  \nKey words: phosphoglycerate dehydrogenase/metabolism; ovarian neoplasms/pathology; humans; carcinoma; ovarian epithelial/drug therapy; female.  \nIntroduction  \nOvarian cancer is the deadliest gynecological malignancy in Western countries,1 with high-grade serous (HGSOC) being the most prevalent subtype. Standard treatment is platinumbased chemotherapy combined with debulking surgery2; however, the vast majority of patients develop recurrent disease. Metabolic reprogramming is linked to malignant proliferation and recurrent disease3 and is emerging as a possible source of therapeutic targets. The de novo serine synthesis pathway (SSP; Figure 1) plays a crucial role in tumor metabolic adaptation and carcinogenesis and is mediated by phosphoglycerate dehydrogenase (PHGDH) .4 The prognostic value of PHGDH has been shown in multiple cancers,5 yet little is known about its role in HGSOC. In this study, we examined PHGDH as a prognostic biomarker of survival in HGSOC.  \nMethods  \nWe included 322 women with FIGO stage 2b-4 HGSOC who received either primary debulking surgery followed by  \nadjuvant chemotherapy or neoadjuvant chemotherapy and interval debulking (NACT-IDS), in one of 3 Dutch referral hospitals (Netherlands Cancer Institute (NKI-AVL), Maastricht University Medical Center and Amsterdam University Medical Center) between 2008 and 2015. Patient data were extracted from the Netherlands Cancer Registry (NCR) . Pathological data and tumor blocks were obtained from the Dutch Nationwide Pathology Databank (PALGA) . Institutional review board approval of the NCR (K19.074), PALGA (2019-169), and NKI-AVL (CFMPB297) was obtained. The dataset was anonymous and exempt from ethics review board appr","cbCailXmyIsh31My","https://ap.wps.com/l/cbCailXmyIsh31My","pdf",8113907,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Materials and Methods (Patient selection and assays)\n# Survival analysis and statistics","[{\"question\":\"What is the main prognostic question addressed in the study?\",\"answer\":\"The study evaluates whether phosphoglycerate dehydrogenase (PHGDH) expression predicts survival outcomes in high-grade serous ovarian cancer (HGSOC).\"},{\"question\":\"How was PHGDH expression measured and categorized?\",\"answer\":\"PHGDH expression was assessed by immunohistochemistry and scored by staining intensity multiplied by the percentage of positive cells, then grouped into “low” or “high” using a survival-discriminative cutoff.\"},{\"question\":\"What clinical factors were associated with PHGDH-high tumors?\",\"answer\":\"PHGDH-high tumors were linked to higher FIGO stage and increased use of neoadjuvant chemotherapy.\"}]","High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer | PDF",1790022131,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33b5c8558e2388d569b2af3b9c6f7152.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/415de47ba7baf6baa79bf68f0d370fdf.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d1bdb556e68c8fceb9f1138a1045420.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db3607354565d8a0cb0588026268b8ab.webp",980,1287]